Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS

Renaissance Technologies LLC cut its position in shares of Evolus, Inc. (NASDAQ:EOLS) by 57.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 339,025 shares of the company’s stock after selling 460,875 shares during the quarter. Renaissance Technologies LLC owned about 0.51% of Evolus worth $1,393,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of EOLS. Larson Financial Group LLC raised its holdings in Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after buying an additional 2,837 shares during the period. Meeder Asset Management Inc. acquired a new position in Evolus during the fourth quarter valued at approximately $34,000. Wexford Capital LP purchased a new stake in Evolus during the third quarter worth approximately $37,000. Aquatic Capital Management LLC purchased a new stake in Evolus during the third quarter worth approximately $48,000. Finally, State of Wyoming acquired a new stake in shares of Evolus in the fourth quarter worth $63,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EOLS has been the topic of several recent research reports. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, BTIG Research reissued a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Wednesday, June 17th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Evolus presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Evolus Price Performance

EOLS opened at $8.12 on Thursday. Evolus, Inc. has a 12-month low of $3.86 and a 12-month high of $8.43. The stock has a market capitalization of $536.33 million, a PE ratio of -15.62 and a beta of 1.35. The firm’s fifty day moving average price is $6.61 and its 200 day moving average price is $5.61.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.